Ozempic Injection Sites: Clinical Guidance for Optimal Absorption

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Subcutaneous injection sites for GLP-1 medications like semaglutide and tirzepatide are typically the abdomen, thigh, or upper arm. Rotating injection sites every week helps prevent lipohypertrophy—abnormal fat buildup—which can reduce medication absorption by up to 25 percent.

Injection technique matters more than many patients realize. Beyond site selection, your individual physiology, body composition, and genetic factors in GLP-1 receptor pathways influence how efficiently your body responds to compounded GLP-1 therapy, making personalized provider guidance essential.

Subcutaneous Anatomy and Why Site Selection Matters

Subcutaneous tissue lies between skin and muscle, providing consistent absorption for peptide medications. The abdomen, outer thigh, and upper arm contain sufficient fat depth for proper needle placement. Insulin and GLP-1 medications are injected into this layer, not muscle or dermis.

Site rotation prevents lipohypertrophy and lipotrophy, conditions that distort normal fat architecture and impair drug absorption. Studies show patients using the same injection site repeatedly experience slower, less predictable medication uptake. Rotating sites weekly maintains consistent bioavailability.

Injection Site Rotation Framework and Best Practices

A structured rotation system ensures consistent medication delivery. The abdomen offers the fastest absorption, followed by the thigh, then the upper arm. Weekly rotation within one body region, then switching regions monthly, optimizes absorption variability while preventing tissue damage.

Proper technique includes using a 4–6 mm needle at 90 degrees, pinching skin gently, and injecting slowly. Allow 10 seconds before withdrawing the needle. Inspect injection sites monthly for dimpling, thickening, or swelling that suggests lipohypertrophy.

Injection Site	Absorption Speed	Best Practice	Caution
Abdomen	Fastest (15–30 min)	2 inches from navel; rotate sites within region	Avoid scar tissue and active inflammation
Outer Thigh	Moderate (30–45 min)	Upper-outer quadrant; alternate legs weekly	Avoid areas prone to friction or pressure
Upper Arm	Slowest (45–60 min)	Back of triceps area; rotate between arms	Ensure adequate subcutaneous depth in lean patients
Buttocks	Variable (45–90 min)	Not typically recommended for GLP-1 medications	Greater variability; may increase side effects

How Body Composition and Anatomy Influence Absorption

Subcutaneous fat thickness affects medication absorption rates. Patients with less subcutaneous tissue may experience faster, potentially more variable absorption. Conversely, greater fat depth provides more stable absorption kinetics but requires consistent site rotation to prevent lipohypertrophy complications.

Individual differences in blood flow, vascularization, and tissue density also influence how quickly injected GLP-1 medications enter systemic circulation. These anatomical and physiological factors partly explain why some patients experience different response timelines or side effect profiles at identical doses.

Genetic Factors, Lipohypertrophy Risk, and Provider Consultation

While injection technique is modifiable, genetic variations in fatty tissue development and inflammatory pathways may predispose some individuals to accelerated lipohypertrophy or altered absorption patterns. Understanding your genetic profile in GLP-1 and metabolic pathways can inform your provider's recommendations for site rotation frequency and injection technique adjustments.

Always discuss injection technique, site selection, and any concerns about tissue changes with your healthcare provider. They can assess your individual anatomy, monitor for complications, and adjust your treatment plan based on your response and any adverse tissue changes observed during follow-up visits.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals genetic predispositions in GLP-1 receptor pathways, FTO variants, and metabolic response genes—insights that may help provide context for how your body metabolizes and responds to compounded GLP-1 medications like semaglutide and tirzepatide. These genetic markers should be interpreted with a qualified healthcare provider to inform personalized dosing and monitoring strategies.

The genetic test examines variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. While these markers reveal predispositions in peptide metabolism and receptor sensitivity, they do not predict your exact medication response. Genetic insights complement—never replace—clinical evaluation and injection technique optimization.

When combined with proper injection site selection and rotation, understanding your genetic predispositions in GLP-1 pathways can support a more informed conversation with your provider about whether compounded semaglutide, tirzepatide, or alternative peptide protocols may align best with your individual physiology and treatment goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.